Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019 with GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Co & Tesaro Dominating

04 Nov, 2015, 07:10 ET from Research and Markets

DUBLIN, Nov. 4, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/cb499f/global) has announced the addition of the "Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019" report to their offering.

The analysts forecast the global chemotherapy induced nausea and vomiting drugs market to grow at a CAGR of 4.9% over the period 2014-2019.

Based on the type of CINV, different treatment regimens are prescribed. The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. Most of the drugs used in the treatment are helpful in the prevention of vomiting but show less effect in treating nausea.

The report, Global CINV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global CINV drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

One major trend in the market is individuals tend to develop resistance to monotherapies over a period of time, resulting in the increased preference for combination therapies. These combination therapies have a better safety and efficacy profile, increasing their preference for treating CINV.

According to the report, one key driver of this market is patent expiries result in the loss of market exclusivity of a drug, leading to a rapid decline in its sales. This leads to the market entry of generic forms that have a similar efficacy and safety profile as the branded drug and are available at low prices. The patents of most of the CINV drugs have either expired or are set to expire by the end of the forecast period.

Further, the report states that one of the major challenges in the market is off-label drugs are unapproved medications, but show efficacy in the treatment of the condition. Many off-label drugs are used to manage CINV. Corticosteroids, such as dexamethasone, are commonly used to treat CINV.

Key vendors

  • GlaxoSmithKline
  • Helsinn
  • Heron Therapeutics
  • Merck & Co
  • Tesaro

Other prominent vendors

  • Acacia Pharma
  • Aphios
  • Barr Laboratories
  • Baxter Healthcare
  • Eisai
  • Especificos Stendhal
  • F.Hoffmann La Roche
  • Mundipharma
  • Mylan Pharmaceuticals
  • OPKO Health
  • Orchid Healthcare
  • Otsuka Pharmaceutical
  • ProStrakan
  • Sandoz (Novartis)
  • Solvay Pharmaceuticals
  • Specialised Therapeutics Australia
  • Sun Pharma
  • Taiho Pharmaceutical
  • Teva Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/cb499f/global

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com